Counselors in Greensboro, GA Accepting Medicare

2 Counselors found. Showing 1 - 2

Ms. Annette Jackson Benneche, LPC, M.S., M.ED. Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 110 N Main St, Greensboro, GA 30642 Phone: 706-453-7400    Fax: 855-898-5414

Mrs. Donna S Eaton, LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 1024 Founders Row, Greensboro, GA 30642 Phone: 706-347-0774

News Archive

RG7204 Phase III study shows significant survival benefit in patients with metastatic melanoma

Genentech, a member of the Roche Group, today announced that BRIM3, a Phase III clinical study of RG7204, met its co-primary endpoints showing a significant survival benefit in people with previously untreated BRAF V600 mutation-positive metastatic melanoma.

Immunomodulator induces long-term anti-tumor activity

EntreMed, Inc., a clinical-stage biopharmaceutical company developing therapeutic candidates primarily for the treatment of cancer, today reported that three months following administration with ENMD 0996, preclinical animal models showed inhibition of metastases. Data presented demonstrated that ENMD 0996 specifically blocks the activity of basic fibroblast growth factor (FGF-2), a naturally-occurring protein that stimulates angiogenesis, but had no effect on other angiogenesis stimulators.

Eli Lilly reports positive results from Phase III AWARD trials of type 2 diabetes drug, dulaglutide

Eli Lilly and Company today announced positive top-line results of two additional Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a once-weekly treatment for type 2 diabetes.

Despite reduced HIV/AIDS deaths, disease still persists in South Africa

After peaking in 2007, AIDS mortality in South Africa has decreased with the widespread introduction of effective antiretroviral therapy, according to updated estimates published in AIDS, official journal of the International AIDS Society. AIDS is published by Wolters Kluwer.

CEL-SCI to raise $4.4 million by selling 9.7 million units to institutional investors

CEL-SCI Corporation. (NYSE Amex: CVM), a biotechnology company entering a late stage oncology trial and focused on infectious disease, today announced that it has entered into a definitive agreement with several institutional investors to sell 9.7 million units, with each unit consisting of one of the Company's common shares and 0.50 warrants to purchase one share of common stock, for gross proceeds of approximately $4.4 million, before deducting placement agent fees and estimated offering expenses, in a "registered direct" offering.

Read more Medical News

› Verified 8 days ago